Purchase Order HHSN261201700290P

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,480.00 on May 22, 2020, with completion scheduled for June 29, 2021. Work is performed in San Diego, California. The order is firm fixed price with no set-aside designation. Acea Biosciences is a subsidiary of Agilent Technologies and supplies life sciences instrumentation, software, consumables, and services to federal research organizations.</p>

The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $22,504.00 on March 1, 2018, with a completion date of August 31, 2018. The order is a firm fixed price, commercial acquisition with no small business set-aside. Performance takes place in Bethesda, Maryland. The procurement covers specialized life sciences equipment, instrumentation, or related services aligned with Acea's portfolio of flow cytometry, cell analysis, and biosensing products for research...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $32,593.00 on August 7, 2019, for in vitro testing of anti-cancer therapeutics using Xcelligence technology. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 6, 2019.</p>

<p>The National Cancer Institute issued a purchase order to Acea Biosciences, Inc. on June 27, 2019 for maintenance agreement services with a ceiling value of $15,627.60 and an ultimate completion date of June 29, 2020. Place of performance is San Diego, California. The order was awarded under firm fixed price on a no-set-aside basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for extended warranty services valued at $3,004.32 on February 20, 2020, with an ultimate completion date of February 28, 2021. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation. This purchase order was issued to de-obligate fiscal year 2020 expiring lines per NIH OALM communication 25-06.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. valued at $4,275.00 on February 5, 2020, for a service agreement to de-obligate expiring FY20 lines. Work is performed at Bethesda, Maryland. The order carries firm fixed pricing and completed on February 28, 2021. No set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $2,916.59 on July 1, 2014, for preventative maintenance service on an Xcelligence DP invasion machine (Serial # 32-1110-1728-7). Performance is in Bethesda, Maryland, with completion by June 30, 2015. The order was placed under firm fixed-price terms with no small business set-aside.</p>

This federal contract award to Acea Biosciences, Inc. was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract, valued at $96,213.60, is for the procurement of a small footprint high-dimensional flow cytometer. This equipment will be used to support research activities within the NCI. The contract has a firm fixed price pricing type and a completion date of November 16, 2016. Acea Biosciences is a life sciences company...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for one year of extended service warranty coverage for a Novo Cyte Three laser system, valued at $11,958.00, with an award date of November 30, 2018. Place of performance is Bethesda, Maryland. The warranty period runs through November 29, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $48,544.00 on August 7, 2026, with an ultimate completion date of August 6, 2027. The order is firm fixed price with no set-aside applied. Work is performed in Carlsbad, California. The purchase order procures EVOS M7000 laboratory imaging equipment.</p>